Author:
Koto Prosper,Tennankore Karthik,Vinson Amanda,Krmpotic Kristina,Weiss Matthew J.,Theriault Chris,Beed Stephen
Abstract
Abstract
Background
This study was an ex-ante cost-utility analysis of deemed consent legislation for deceased organ donation in Nova Scotia, a province in Canada. The legislation became effective in January 2021. The study's objective was to assess the conditions necessary for the legislation change’s cost-effectiveness compared to expressed consent, focusing on kidney transplantation (KT).
Method
We performed a cost-utility analysis using a Markov model with a lifetime horizon. The study was from a Canadian payer perspective. The target population was patients with end-stage kidney disease (ESKD) in Atlantic Canada waitlisted for KT. The intervention was the deemed consent and accompanying health system transformations. Expressed consent (before the change) was the comparator. We simulated the minimum required increase in deceased donor KT per year for the cost-effectiveness of the deemed consent. We also evaluated how changes in dialysis and maintenance immunosuppressant drug costs and living donor KT per year impacted cost-effectiveness in sensitivity analyses.
Results
The expected lifetime cost of an ESKD patient ranged from $177,663 to $553,897. In the deemed consent environment, the expected lifetime cost per patient depended on the percentage increases in the proportion of ESKD patients on the waitlist getting a KT in a year. The incremental cost-utility ratio (ICUR) increased with deceased donor KT per year. Cost-effectiveness of deemed consent compared to expressed consent required a minimum of a 1% increase in deceased donor KT per year. A 1% increase was associated with an ICUR of $32,629 per QALY (95% CI: − $64,279, $232,488) with a 81% probability of being cost-effective if the willingness-to-pay (WTP) was $61,466. Increases in dialysis and post-KT maintenance immunosuppressant drug costs above a threshold impacted value for money. The threshold for immunosuppressant drug costs also depended on the percent increases in deceased donor KT probability and the WTP threshold.
Conclusions
The deemed consent legislation in NS for deceased organ donation and the accompanying health system transformations are cost-effective to the extent that they are anticipated to contribute to more deceased donor KTs than before, and even a small increase in the proportion of waitlist patients receiving a deceased donor KT than before the change represents value for money.
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. LEBLANNM. Bill 133 - Human Organ and Tissue Donation Act. Nova Scotia Legislature. 2019. https://nslegislature.ca/legc/bills/63rd_2nd/1st_read/b133.html. Accessed 3 Feb 2021.
2. Bilgel F. The impact of presumed consent laws and institutions on deceased organ donation. Eur J Health Econ. 2012;13:29–38.
3. DeRoos LJ, Marrero WJ, Tapper EB, Sonnenday CJ, Lavieri MS, Hutton DW, et al. Estimated association between organ availability and presumed consent in solid organ transplant. JAMA Netw Open. 2019;2: e1912431.
4. Etheredge HR. Assessing global organ donation policies: opt-in vs opt-out. RMHP. 2021;14:1985–98.
5. Ahmad MU, Hanna A, Mohamed A-Z, Schlindwein A, Pley C, Bahner I, et al. A systematic review of opt-out versus opt-in consent on deceased organ donation and transplantation (2006–2016). World J Surg. 2019;43:3161–71.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献